CO51 Safety Profile of Approved Alzheimer's Medication By USFDA
ADRD will affect 6.7 million Americans aged 65+ in 2023, expected to double by 2050. Pharmacological management includes two symptomatic approaches: inhibition of acetylcholinesterase (donepezil, galantamine, rivastigmine) and N-methyl-D-aspartate receptors. Recommended treatments are AChEIs for mild-moderate AD. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Almutairi, V. Sanogo, K. Diaby Source Type: research
Sex-specific effects of neuromodulatory drugs on normal and stress-induced social dominance and aggression in rats
ConclusionThese results showed that Risperidone has stronger effects on male social behavior whereas Paroxetine and Donepezil differentially affect social abilities in both sexes during normal and stressed situations. (Source: Psychopharmacology)
Source: Psychopharmacology - November 23, 2023 Category: Psychiatry Source Type: research
Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review
CONCLUSION: TTSs are primarily effective for delivering small molecules. The use of absorption enhancers and irritation mitigators can be necessary to enhance the performance. The development of these technologies is essential for the convenience of patients and caregivers.PMID:37990896 | DOI:10.2174/0118715273275957231102044934 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 22, 2023 Category: Drugs & Pharmacology Authors: Let ícia Basso Silvia Cristina Fagundes Tatiana Staudt Karini da Rosa Elizane Langaro Hamid Omidian Charise Dallazem Bertol Source Type: research
Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3 β(Ser9)/Nrf2 signaling pathway
This study aims to explore the role of PTN in treating AD. Our in vitro findings underscore PTN's bioactivity, as evidenced by its capacity to curtail apoptosis, reduce reactive oxygen species (ROS) production, and restore mitochondrial membrane potential in PC12 cells. Moreover, PTN treatment demonstrates a capacity to ameliorate deficits in spatial learning and memory in the 3 ×Tg-AD murine model. Notably, PTN's therapeutic efficacy surpasses that of a clinical agent, donepezil. Mechanistically, PTN's neuroprotective effects stem from its adept regulation of the AMPK/GSK3β(ser9)/Nrf2 signaling pathway and protection on...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 22, 2023 Category: Drugs & Pharmacology Authors: Jinfeng Sun Liwei Li Li Xiong Fan Chen Lingyu She Hao Tang Yuqing Zeng Ying Duan Luyao Li Wei Wang Gao Li Xia Zhao Guang Liang Source Type: research
Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review
CONCLUSION: TTSs are primarily effective for delivering small molecules. The use of absorption enhancers and irritation mitigators can be necessary to enhance the performance. The development of these technologies is essential for the convenience of patients and caregivers.PMID:37990896 | DOI:10.2174/0118715273275957231102044934 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 22, 2023 Category: Drugs & Pharmacology Authors: Let ícia Basso Silvia Cristina Fagundes Tatiana Staudt Karini da Rosa Elizane Langaro Hamid Omidian Charise Dallazem Bertol Source Type: research
Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3 β(Ser9)/Nrf2 signaling pathway
This study aims to explore the role of PTN in treating AD. Our in vitro findings underscore PTN's bioactivity, as evidenced by its capacity to curtail apoptosis, reduce reactive oxygen species (ROS) production, and restore mitochondrial membrane potential in PC12 cells. Moreover, PTN treatment demonstrates a capacity to ameliorate deficits in spatial learning and memory in the 3 ×Tg-AD murine model. Notably, PTN's therapeutic efficacy surpasses that of a clinical agent, donepezil. Mechanistically, PTN's neuroprotective effects stem from its adept regulation of the AMPK/GSK3β(ser9)/Nrf2 signaling pathway and protection on...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 22, 2023 Category: Drugs & Pharmacology Authors: Jinfeng Sun Liwei Li Li Xiong Fan Chen Lingyu She Hao Tang Yuqing Zeng Ying Duan Luyao Li Wei Wang Gao Li Xia Zhao Guang Liang Source Type: research
Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review
CONCLUSION: TTSs are primarily effective for delivering small molecules. The use of absorption enhancers and irritation mitigators can be necessary to enhance the performance. The development of these technologies is essential for the convenience of patients and caregivers.PMID:37990896 | DOI:10.2174/0118715273275957231102044934 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 22, 2023 Category: Drugs & Pharmacology Authors: Let ícia Basso Silvia Cristina Fagundes Tatiana Staudt Karini da Rosa Elizane Langaro Hamid Omidian Charise Dallazem Bertol Source Type: research
Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review
CONCLUSION: TTSs are primarily effective for delivering small molecules. The use of absorption enhancers and irritation mitigators can be necessary to enhance the performance. The development of these technologies is essential for the convenience of patients and caregivers.PMID:37990896 | DOI:10.2174/0118715273275957231102044934 (Source: CNS and Neurological Disorders Drug Targets)
Source: CNS and Neurological Disorders Drug Targets - November 22, 2023 Category: Drugs & Pharmacology Authors: Let ícia Basso Silvia Cristina Fagundes Tatiana Staudt Karini da Rosa Elizane Langaro Hamid Omidian Charise Dallazem Bertol Source Type: research
Piperazine-2-carboxylic acid derivatives as MTDLs anti-Alzheimer agents: Anticholinesterase activity, mechanistic aspect, and molecular modeling studies
Bioorg Chem. 2023 Oct 21;142:106916. doi: 10.1016/j.bioorg.2023.106916. Online ahead of print.ABSTRACTDevelopment of Multitarget-Directed Ligands (MTDLs) is a promising approach to combat the complex etiologies of Alzheimer's disease (AD). Herein we report the design, synthesis, and characterization of a new series of 1,4-bisbenzylpiperazine-2-carboxylic acid derivatives 3-5(a-g), 7a-f, 8a-s, and their piperazine-2-yl-1,3,4-oxadiazole analogs 6a-g. In vitro inhibitory effect against Electrophorus electricus acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) from Equine serum was evaluated using modified Ellman's ...
Source: Bioorganic Chemistry - November 1, 2023 Category: Chemistry Authors: Aya M Soliman Hend A A Abd El-Wahab Hulya Akincioglu İlhami Gülçin Farghaly A Omar Source Type: research
Piperazine-2-carboxylic acid derivatives as MTDLs anti-Alzheimer agents: Anticholinesterase activity, mechanistic aspect, and molecular modeling studies
Bioorg Chem. 2023 Oct 21;142:106916. doi: 10.1016/j.bioorg.2023.106916. Online ahead of print.ABSTRACTDevelopment of Multitarget-Directed Ligands (MTDLs) is a promising approach to combat the complex etiologies of Alzheimer's disease (AD). Herein we report the design, synthesis, and characterization of a new series of 1,4-bisbenzylpiperazine-2-carboxylic acid derivatives 3-5(a-g), 7a-f, 8a-s, and their piperazine-2-yl-1,3,4-oxadiazole analogs 6a-g. In vitro inhibitory effect against Electrophorus electricus acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) from Equine serum was evaluated using modified Ellman's ...
Source: Bioorganic Chemistry - November 1, 2023 Category: Chemistry Authors: Aya M Soliman Hend A A Abd El-Wahab Hulya Akincioglu İlhami Gülçin Farghaly A Omar Source Type: research
Molecular docking analysis of acetylcholinesterase inhibitors for Alzheimer's disease management
This study suggests that further experimental investigations can be conducted on Ginkgolide A and Licorice glycoside D2 to explore their potential therapeutic applications for AD.PMID:37886145 | PMC:PMC10599677 | DOI:10.6026/97320630019565 (Source: Bioinformation)
Source: Bioinformation - October 27, 2023 Category: Bioinformatics Authors: Israa J Hakeem Source Type: research
Molecular docking analysis of acetylcholinesterase inhibitors for Alzheimer's disease management
This study suggests that further experimental investigations can be conducted on Ginkgolide A and Licorice glycoside D2 to explore their potential therapeutic applications for AD.PMID:37886145 | PMC:PMC10599677 | DOI:10.6026/97320630019565 (Source: Bioinformation)
Source: Bioinformation - October 27, 2023 Category: Bioinformatics Authors: Israa J Hakeem Source Type: research
Molecular docking analysis of acetylcholinesterase inhibitors for Alzheimer's disease management
This study suggests that further experimental investigations can be conducted on Ginkgolide A and Licorice glycoside D2 to explore their potential therapeutic applications for AD.PMID:37886145 | PMC:PMC10599677 | DOI:10.6026/97320630019565 (Source: Bioinformation)
Source: Bioinformation - October 27, 2023 Category: Bioinformatics Authors: Israa J Hakeem Source Type: research
Neurobehavioral impairments from chromium exposure: Insights from a zebrafish model and drug validation
Comp Biochem Physiol C Toxicol Pharmacol. 2023 Oct 24:109780. doi: 10.1016/j.cbpc.2023.109780. Online ahead of print.ABSTRACTWe have developed a zebrafish model to explore the alterations in neurobehaviors resulting from both acute and chronic exposure to chromium (Cr). Zebrafish exposed to half (HC group: 19.7 mg/L) and a quarter (LC group: 9.85 mg/L) of the LD50 concentration of Cr for a span of 2 weeks exhibited aberrant locomotion, heightened anxiety, cognitive impairment, and reduced aggression - hallmark traits reminiscent of an Alzheimer's Disease (AD)-like syndrome. Furthermore, Zebrafish exposed to an environmenta...
Source: Physiological Research - October 26, 2023 Category: Physiology Authors: Seenivasan Boopathi B Haridevamuthu Akash Gandhi S P Ramya Ranjan Nayak Gokul Sudhakaran R Rajakrishnan Selvaraj Arokiyaraj Jesu Arockiaraj Source Type: research
Neurobehavioral impairments from chromium exposure: Insights from a zebrafish model and drug validation
Comp Biochem Physiol C Toxicol Pharmacol. 2023 Oct 24:109780. doi: 10.1016/j.cbpc.2023.109780. Online ahead of print.ABSTRACTWe have developed a zebrafish model to explore the alterations in neurobehaviors resulting from both acute and chronic exposure to chromium (Cr). Zebrafish exposed to half (HC group: 19.7 mg/L) and a quarter (LC group: 9.85 mg/L) of the LD50 concentration of Cr for a span of 2 weeks exhibited aberrant locomotion, heightened anxiety, cognitive impairment, and reduced aggression - hallmark traits reminiscent of an Alzheimer's Disease (AD)-like syndrome. Furthermore, Zebrafish exposed to an environmenta...
Source: Comparative biochemistry and physiology. Toxicology and pharmacology : CBP - October 26, 2023 Category: Biochemistry Authors: Seenivasan Boopathi B Haridevamuthu Akash Gandhi S P Ramya Ranjan Nayak Gokul Sudhakaran R Rajakrishnan Selvaraj Arokiyaraj Jesu Arockiaraj Source Type: research
